Canagliflozin: A Comprehensive Review of Advances in Preclinical Research

Abstract

Canagliflozin is a synthetic sodium glucose transporter inhibitor (SGLT2i). It is the latest approved class of medicine used in the treatment of type 2 diabetes mellitus. As diabetes is emerging as the most common metabolic disorder, SGLT2i has lightened up the path of treatment with additional benefits. SGLT2 is located in the proximal convoluted tubules of the nephron and is responsible for glucose reabsorption. Thus, inhibiting the SGLT2 leads to a decline in glucose concentration in the plasma. The secondary effects of canagliflozin, such as cardiac protection, renoprotective, and decreased obesity, have made it more putative in the treatment of diabetes mellitus. There are some side effects of canagliflozin, such as volume depletion, genital and urinary tract infection, and lower limb amputation, which could be a matter of concern for patients. Being an anti-diabetic drug, canagliflozin also possesses anti-inflammatory and anti-cancer properties. Several studies have been conducted to determine the efficacy of canagliflozin as an anti-cancer agent. Its pharmacokinetics indicate rapid absorption, reaching peak plasma concentrations within 1–2 hours. With a half-life of approximately 12 hours, it undergoes minimal hepatic metabolism and is primarily excreted unchanged via urine. Common adverse drug reactions (ADRs) include urinary tract infections and dehydration. Clinical trials on canagliflozin, both alone and in combination with other diabetes complications, have been conducted, with some completed and others in various phases. This review article contains information about the pharmacokinetics, drug safety, and efficacy profile of canagliflozin, along with details regarding toxicological studies of canagliflozin.

Keywords

canagliflozin - SGLT-2 inhibitors - sodium-glucose transporter - obesity - drug safety - heart failure

Publikationsverlauf

Eingereicht: 05. Februar 2025

Angenommen: 31. März 2025

Artikel online veröffentlicht:
28. April 2025

• References

• 1 Saeedi P, Petersohn I, Salpea P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 2019; 157: 107843
• 2 Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 2021; 69: 2932-2938
• 3 Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Heal Sci Reports 2024; 7: e2004
• 4 Antar SA, Ashour NA, Sharaky M. et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother 2023; 168: 115734
• 5 Committee ADAPP, ElSayed NA, McCoy RG. et al. Summary of Revisions: Standards of Care in Diabetes—2025. Diabetes Care 2025; 48: S6-S13
• 6 Luk A. Changing landscape of diabetes in Asia–What are the unmet needs?. J Diabetes Investig 2024; 15: 402-409
• 7 Ali M, Alam MM, Rifat M. et al. Prevalence of diabetes and prediabetes in South Asian countries: a systematic review and meta-analysis. Discov Public Heal 2025; 22: 39-58
• 8 Ranasinghe P, Rathnayake N, Wijayawardhana S. et al. Rising trends of diabetes in South Asia: A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev 2024; 18: 103160
• 9 Singh A, Afshan N, Singh A. et al. Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review. Eur J Cell Biol 2023; 102: 151329
• 10 Tegegne BA, Adugna A, Yenet A. et al. A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. Front Endocrinol (Lausanne) 2024; 15: 1440456
• 11 Guo YY, Zhang JY, Sun JF. et al. A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications. Eur J Med Chem 2024; 267: 116185-116198
• 12 Jakher H, Chang TI, Tan M. et al. Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes, Metab Syndr Obes Targets Ther 2019; 12: 209-215
• 13 Patel S, Gohel K, Gordhanbhai Patel B. A Systematic Review on Effect of Canagliflozin in Special Population. Curr Diabetes Rev 2016; 12: 211-222
• 14 Ganguly A, Datta A, Jana M. et al. An Overview of Canagliflozin. World J Pharm Pharm Sci 2024; 13: 1303-1318
• 15 Kaushal S, Singh H, Thangaraju P. et al. Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. N Am J Med Sci 2014; 6: 107-113
• 16 Triplitt C, Cornell S. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes 2015; 8: 73-81
• 17 Prasanna K, Ghosh S, Canovatchel W. et al. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2017; 21: 196-209
• 18 Nomura S, Sakamaki S, Hongu M. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355-6360
• 19 Nigro SC, Riche DM, Pheng M. et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother 2013; 47: 1301-1311
• 20 Iijima H, Kifuji T, Maruyama N. et al. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther 2015; 32: 768-782
• 21 Devineni D, Polidori D. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet 2015; 54: 1027-1041
• 22 Devineni D, Curtin CR, Polidori D. et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610
• 23 Cefalu WT, Leiter LA, Yoon KH. et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950
• 24 Davis SN. Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert Rev Clin Pharmacol 2014; 7: 21-23
• 25 Forst T, Guthrie R, Goldenberg R. et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477
• 26 Wilding JPH, Charpentier G, Hollander P. et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282
• 27 Rosenstock J, Aggarwal N, Polidori D. et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238
• 28 Wanner C. EMPA-REG OUTCOME: The Nephrologistʼs Point of View. Am J Cardiol 2017; 120: S59-S67
• 29 Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther 2019; 10: 1771-1792
• 30 Heerspink H, Perkins B, Fitchett D. et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016; 134: 10-30
• 31 Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Am J Kidney Dis 2018; 72: 267-277
• 32 Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest 2023; 133: 29-36
• 33 Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation 2017; 136: 1548-1559
• 34 Bankir L, Roussel R, Bouby N. Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Renal Physiol 2015; 309: F2-F23
• 35 Kao TW, Huang CC. Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Front Cardiovasc Med 2022; 9: 1086672
• 36 Xu C, Wang W, Zhong J. et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol 2018; 152: 45-59
• 37 Uthman L, Kuschma M, Römer G. et al. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells. Cardiovasc Drugs Ther 2020; 35: 1083-1094
• 38 Hasan R, Lasker S, Hasan A. et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci Rep 2020; 10: 14459-14472
• 39 Peyton KJ, Behnammanesh G, Durante GL. et al. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. Int J Mol Sci 2022; 23: 8777-8789
• 40 Li X, Kerindongo RP, Preckel B. et al. Canagliflozin inhibits inflammasome activation in diabetic endothelial cells – Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells. Biomed Pharmacother 2023; 159: 114228-114239
• 41 Nandhidha R, Punnagai K. Evaluation of Anti-Inflammatory and Wound Healing Potential of Sodium Glucose Co-Transporter2 (SGLT2) Inhibitors. Res J Pharm Technol 2022; 15: 4457-4462
• 42 Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab 2019; 21: 1291-1298
• 43 Schönberger E, Mihaljević V, Steiner K. et al. Immunomodulatory Effects of SGLT2 Inhibitors-Targeting Inflammation and Oxidative Stress in Aging. Int J Environ Res Public Health 2023; 20: 6671
• 44 Huang H, Huang B, Li Y. et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16: 15-24
• 45 Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447
• 46 Zoppini G, Targher G, Chonchol M. et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012; 35: 99-104
• 47 Lytvyn Y, Perkins BA, Cherney DZI. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 2015; 39: 239-246
• 48 Iqbal N, Ambery P, Logue J. et al. Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism. Diabetes Res Clin Pract 2023; 199: 110669
• 49 Dutka M, Bobiński R, Francuz T. et al. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. Cancers (Basel) 2022; 14: 5811-5819
• 50 Tang H, Dai Q, Shi W. et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia 2017; 60: 1862-1872
• 51 Villani LA, Smith BK, Marcinko K. et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab 2016; 5: 1048-1056
• 52 Hung MH, Chen YL, Chen LJ. et al. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation. Cell Death Dis 2019; 10: 420-432
• 53 Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov 2019; 18: 527-551
• 54 Vinay N, David DC. Evaluation and comparison of anti-cancer activity of dapagliflozin and canagliflozin in oral cancer cell line: an in vitro study. Int J Basic Clin Pharmacol 2019; 8: 473-477
• 55 Jiang D, Ma P. Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis. Front Oncol 2022; 12: 1057455
• 56 Yamamoto L, Yamashita S, Nomiyama T. et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int 2021; 12: 389-398
• 57 Shoda K, Tsuji S, Nakamura S. et al. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK. Cell Mol Neurobiol 2023; 43: 879-892
• 58 Ali A, Mekhaeil B, Biziotis OD. et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol 2023; 6: 919-933
• 59 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657
• 60 Wei D, Liao L, Wang H. et al. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro. Life Sci 2020; 247: 117414-117426
• 61 Matsuba I, Takihata M, Takai M. et al. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. Diabetes, Obes Metab 2021; 23: 2614-2622
• 62 Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 2019; 79: 219-230
• 63 Khalid Z, Patel P. Canagliflozin. Compr Med Chem III 2024; 8–8: 349-365
• 64 Jesus DJB, Conceição DRA, Machado TR. et al. Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach. An Acad Bras Cienc 2022; 94: e20211287
• 65 Bakhtyari NG, Raitano G, Benfenati E. et al. Comparison of in silico models for prediction of mutagenicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013; 31: 45-66
• 66 Garcia AR, Oliveira DMP, Jesus JB. et al. Identification of Chalcone Derivatives as Inhibitors of Leishmania infantum Arginase and Promising Antileishmanial Agents. Front Chem 2021; 8: 624678
• 67 Sander T, Freyss J, Von Korff M. et al. DataWarrior: An open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015; 55: 460-473
• 68 Guerra LR, de Souza AMT, Côrtes JA. et al. Assessment of predictivity of volatile organic compounds carcinogenicity and mutagenicity by freeware in silico models. Regul Toxicol Pharmacol 2017; 91: 1-8
• 69 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
• 70 Fathy Elhabal S, El-Nabarawi MA, Abdelaal N. et al. Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study. Drug Deliv 2023; 30: 2241665-2241665
• 71 Angelopoulou A, Kolokithas-Ntoukas A, Papaioannou L. et al. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy. Nanomedicine 2018; 13: 2435-2454
• 72 Patil S, Bahadure S, Patil S. Formulation of canagliflozin hemihydrate-loaded bilosomes for the treatment of Type-2 diabetes mellitus: In vitro, in vivo and in silico molecular docking studies. J Drug Deliv Sci Technol 2023; 86: 104630
• 73 Jassem NA, Abd Alhammid SN. Formulation and Evaluation of Canagliflozin Self-nanomicellizing Solid Dispersion Based on Rebaudioside A for Dissolution and Solubility Improvement. Iraqi J Pharm Sci 2024; 33: 43-56
• 74 Zhao Na Cheng Zhou Qin Lian Gang Wu Dingmei. Canagliflozin composition and preparation method thereof. CN115957183A, 2021
• 75 Padmanaban P, Rachh PR. Nanosuspension of Poorly Soluble Anti-Diabetic Drug for Enhancement of Solubility and Dissolution – Journal of University of Shanghai for Science and Technology. J Univ Shanghai Sci Technol 2021; 23: 516-541
• 76 Patel NC, Patel HA. A recent solidification approach for nanosuspension: formulation, optimisation and evaluation of canagliflozin immediate release pellets. Folia Med (Plovdiv) 2022; 64: 488-500